1.Determination of glycyrrhizic acid in MAHUANG DECOCTION by HPLC when decocted separately or as a whole
Peixue CAO ; Guangyi LIANG ; Bixue XU ; Fengyun JIN ; Zhuying HE ;
Chinese Traditional and Herbal Drugs 1994;0(11):-
Object To determine the content of glycyrrihizic acid obtained when each individual ingredient in MAHUANG DECOCTION was decocted separately and then mixing the extracts with boiling water in comparison with that obtained by decocting the total composition together as a whole in the traditional way. Methods The contents of glycyrrhizic acid was determined by HPLC. Hypersil C 18 column was used, with acetonitrile∶0.1% acetic acid (33∶67) as the mobile phase and detected at the wavelength of 254 nm. Results The average recovery of glycyrrhizic acid when separately decocted was 102.43%, RSD=2.65%, while that of decoction in whole was 99.41%, RSD=3.11%. Conclusion The method was simple and accurate and was not interfered by other constituents in the prescription.
2.Determination of ferulic acid in Tangkuei Blood-Supplementing Decoction by HPLC
Guangyi LIANG ; Bixue XU ; Xia LI ; Peixue CAO ;
Chinese Traditional Patent Medicine 1992;0(02):-
Objective: To compare the contents of ferulic acid in single medicine decoction (preparing the refined granules of single traditional Chinese herb from the different kinds of medicinal materials separately then mixing the granules with boiling water) and mixed medicine decoction (decocting the all kinds of the medicinal materials together as the traditional method) of Tangkuei Blood Supplementing Decoction (composed of Radix Angelicae Sinensis and Radix Astragali). Methods: HPLC conditions: Hypersil C 18 column methanol -0.05% acetic acid solution (45∶55) as mobile phases, detection wavelength at 324 nm. Results: The average recovery of single medicine decoction was 100.86% with RSD =2.33%( n =6), and that of mixed medicine decoction was 101.37% with RSD =1.52%( n =6).Conclusion: The content of ferulic acid mixed medicine decoction was higher than that in single medicine decoction.
3.The Pharmacokinetics of Thyrotropin-releasing Hormone in Rabbits
Jinger XIE ; Keyi XU ; Bixue WU ; Li CHEN ; Min YIN ; Xilin LIAO
Academic Journal of Second Military Medical University 1981;0(04):-
The pharmacokinetics of thyrotropirrreleasing hormone (TRH) made in China was studied in rabbits. TRH concentrations in plasma, urine and various tissues were measured by RIA. After intravenous injection of TRH, the plasma concentration-time curve was shown to fit a two compartment open model with the following pharmacokinetic parameters: 0.8 mg/kg, T1/2?=0.551 min, T1/2? = 9.374 mm, VI = 3.018 ml/kg, Vb = 22.659 ml/kg and AUC = 0.479g. L-1. m-1; 2.0mg/kg, T1/2? = 0.629 mm, T1/2?= 9.734 min, VI = 5.135 ml/kg, Vt = 28.848 ml/kg, and AUC = 0.962g. L-1. m-1; 5.0mg/kg, T1/2? =0.720 min, T1/2?= 10.738 min, VI = 6.120 ml/kg, Vb = 31.928 ml/kg and AUC=2.540 g. L-1. m-1. TRH was distributed widely in tissues and concentrated mainly in the kidney and pituitary. TRH was eliminated partly by the kidney and 21.9% was excreted within 2h after intravenous injection.
4.Synthesis and anti-HBV activity evaluation of Matijin-Su derivatives with aromatic heterocycles
Jingying QIU ; Zhanxing HU ; Bixue XU ; Weidong PAN ; Zhengming HUANG ; Changxiao LIU ; Guangyi LIANG
Journal of China Pharmaceutical University 2015;46(6):641-646
Hepatitis B virus(HBV)-infected hepatitis is one of the most common infectious disease worldwide. To find novel effective anti-HBV agents, a series of Matijin-Su(MTS)derivatives with aromatic heterocycles were synthesized and evaluated for their anti- HBV activities in HepG2 2. 2. 15 cells. Among them, compounds 7a(IC50=2. 94 μmol/L)and 9a(IC50=2. 21 μmol/L)exhibited more potent inhibitory activity against the replication of HBV DNA in HepG2 2. 2. 15 cells than that of lead compound MTS(IC50=11. 16 μmol/L). Notably, both 7a and 9a displayed a high selective index(SI)of 146. 39 and > 250, respectively, which were also much higher than that of MTS(SI=10. 78). Therefore, compounds 7a and 9a may be promising anti-HBV agents with safety profile for HBV infection.